Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States

Rishi J Desai; Ameet Sarpatwari; Nileesa Gautam; Joyce Lii; Michael A Fischer; Joshua J Gagne

doi:10.1001/jama.2019.17521

Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States

JAMA. 2020 Jan 7;323(1):87-89. doi: 10.1001/jama.2019.17521.

Authors

Rishi J Desai¹, Ameet Sarpatwari¹, Nileesa Gautam¹, Joyce Lii¹, Michael A Fischer¹, Joshua J Gagne¹

Affiliation

¹ Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.

Abstract

This pharmacoepidemiology study uses claims data to characterize angiotensin receptor blocker (ARB) prescription trends to evaluate whether recalls of ARBs prompted by discovery of potentially carcinogenic impurities shifted utilization of ARBs individually and as a drug class.

MeSH terms

Angiotensin Receptor Antagonists / therapeutic use*
Drug Prescriptions / statistics & numerical data*
Drug Recalls*
Drug Utilization / statistics & numerical data*
Drugs, Generic / therapeutic use*
Humans
Insurance Claim Review
Insurance, Pharmaceutical Services
United States

Substances

Angiotensin Receptor Antagonists
Drugs, Generic